Midkine is a tumor cell survival factor that displays metastatic and therapeutic resistance functions in uveal melanoma

Karg M, John L, Refaian N, Büttner C, Rottmar T, Sommer J, Bock B, Resheq Y, Ksander B, Heindl LM, Mackensen A, Bosch J (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Investigative Ophthalmology & Visual Science Association for Research in Vision and Ophthalmology (ARVO)

Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC

City/Town: ROCKVILLE

Conference Proceedings Title: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Event location: ONLINE

Authors with CRIS profile

Lukas John Lehrstuhl für Innere Medizin IV Christian Büttner Lehrstuhl für Humangenetik Yazid Resheq Department of Medicine 5 – Haematology and Oncology Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Harvard University US United States (USA) (US) Universität zu Köln DE Germany (DE)

How to cite

APA:

Karg, M., John, L., Refaian, N., Büttner, C., Rottmar, T., Sommer, J.,... Bosch, J. (2020). Midkine is a tumor cell survival factor that displays metastatic and therapeutic resistance functions in uveal melanoma. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ONLINE: ROCKVILLE: ASSOC RESEARCH VISION OPHTHALMOLOGY INC.

MLA:

Karg, Margarete, et al. "Midkine is a tumor cell survival factor that displays metastatic and therapeutic resistance functions in uveal melanoma." Proceedings of the Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), ONLINE ROCKVILLE: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2020.

BibTeX: Download